PY2077235A - Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x - Google Patents

Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x

Info

Publication number
PY2077235A
PY2077235A PY202002077235A PY2077235A PY2077235A PY 2077235 A PY2077235 A PY 2077235A PY 202002077235 A PY202002077235 A PY 202002077235A PY 2077235 A PY2077235 A PY 2077235A PY 2077235 A PY2077235 A PY 2077235A
Authority
PY
Paraguay
Prior art keywords
hepatic
receptor agonists
oxadiazole derivatives
compound
formula
Prior art date
Application number
PY202002077235A
Other languages
English (en)
Spanish (es)
Inventor
Kelly D Boss
Yi Fan
Alec Nathanson Flyer
Declan Hardy
Chihong Huang
Kathryn Taylor Linkens
Jon Christopher Loren
Fupeng Ma
Valentina Molteni
Duncan Shaw
Jeffrey Smith
Catherine Fooks Solovay
Original Assignee
Norvatis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norvatis Ag filed Critical Norvatis Ag
Publication of PY2077235A publication Critical patent/PY2077235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PY202002077235A 2019-11-25 2020-11-20 Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x PY2077235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940061P 2019-11-25 2019-11-25
US202063106293P 2020-10-27 2020-10-27

Publications (1)

Publication Number Publication Date
PY2077235A true PY2077235A (es) 2022-10-31

Family

ID=73654860

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202002077235A PY2077235A (es) 2019-11-25 2020-11-20 Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x

Country Status (22)

Country Link
US (2) US11427586B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065228A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023503320A (cg-RX-API-DMAC7.html)
KR (1) KR20220106778A (cg-RX-API-DMAC7.html)
CN (1) CN114746149A (cg-RX-API-DMAC7.html)
AU (1) AU2020394597B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009942A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157657A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001323A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022006645A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220227A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000107A (cg-RX-API-DMAC7.html)
EC (1) ECSP22040362A (cg-RX-API-DMAC7.html)
IL (1) IL291958A (cg-RX-API-DMAC7.html)
JO (1) JOP20220124A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006151A (cg-RX-API-DMAC7.html)
PE (1) PE20221785A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551248A1 (cg-RX-API-DMAC7.html)
PY (1) PY2077235A (cg-RX-API-DMAC7.html)
TW (1) TW202132289A (cg-RX-API-DMAC7.html)
UY (1) UY38964A (cg-RX-API-DMAC7.html)
WO (1) WO2021105857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243907A1 (en) * 2021-05-20 2022-11-24 Novartis Ag Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
KR102882404B1 (ko) 2022-10-28 2025-11-06 (주)케이메디켐 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
EP2753608A1 (en) * 2011-09-08 2014-07-16 Allergan, Inc. 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
WO2015187840A2 (en) 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
WO2020123869A1 (en) 2018-12-13 2020-06-18 eyeNOS, Inc. Lxr agonist in topical ophthalmic formulation for treatment of dry-eye disorder

Also Published As

Publication number Publication date
JP2023503320A (ja) 2023-01-27
US20220340573A1 (en) 2022-10-27
IL291958A (en) 2022-06-01
PH12022551248A1 (en) 2023-09-11
ECSP22040362A (es) 2022-06-30
MX2022006151A (es) 2022-08-02
EP4065228A1 (en) 2022-10-05
TW202132289A (zh) 2021-09-01
CN114746149A (zh) 2022-07-12
CA3157657A1 (en) 2021-06-03
CR20220227A (es) 2022-06-15
AU2020394597B2 (en) 2024-03-14
KR20220106778A (ko) 2022-07-29
BR112022009942A2 (pt) 2022-08-09
DOP2022000107A (es) 2022-06-15
UY38964A (es) 2021-06-30
CO2022006645A2 (es) 2022-05-31
JOP20220124A1 (ar) 2022-05-23
WO2021105857A1 (en) 2021-06-03
CL2022001323A1 (es) 2023-03-24
US20220064164A1 (en) 2022-03-03
AU2020394597A1 (en) 2022-06-02
PE20221785A1 (es) 2022-11-22
US11427586B2 (en) 2022-08-30

Similar Documents

Publication Publication Date Title
CL2022001323A1 (es) Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x
CO2021017401A2 (es) Agonistas de receptor de melanocortina-4
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
MX2017007658A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo.
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
PY1737795A (es) Solución de dexmedetomidina lista para el uso, premezclada, esterilizable por calor, envasada en un recipiente de plástico flexible
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
UY31780A (es) Fenoxibenzamidas sustituidas
UY37577A (es) Dihidroimidazopiridindionas sustituidas
MX389553B (es) Composicion para incrementar la expresion de pgc-1alfa
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
ECSP19044591A (es) Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina
CO2022003583A2 (es) Compuestos de curcumina y aminoácidos básicos
CO2024001017A2 (es) Compuestos terapéuticos y procedimientos
MX2023011377A (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos.
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2025001109A1 (es) Compuestos derivados de pirazina-carboxamida.
MX2019000744A (es) Formas solidas del inhibidor de la tirosina treonina cinasa (ttk).
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.